July 17, 2007 - Boston Scientific Corp. today announced the implantation of its TAXUS Petal Bifurcation Paclitaxel ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
July 13, 2007 - Biotronik announced that it recently completed the enrollment of the ProLimus I First-In-Man trial to ...
July 12, 2007
June 20, 2007 — Sono-Tek Corporation recently announced the release of the MediCoat PSI, a system which offers ...
June 26, 2007June 20, 2007 — Sono-Tek Corporation recently announced the release of the MediCoat PSI.
The MediCoat PSI offers the ...
June 19, 2007June 15, 2007 — Johnson & Johnson says U.S. regulators have ended almost three years of sanctions over manufacturing ...
June 14, 2007June 1, 2007 — Abbott announced it has completed its application to the U.S. Food and Drug Administration (FDA) ...
May 31, 2007May 30, 2007 -- As concern and investigation continue concerning the link between drug-eluting stents and late-stent ...
May 29, 2007May 29, 2007 — Stentys says the results of preclinical testing of its bifurcated stent were reported at last week's ...
May 28, 2007May 29, 2007 — Abbott announced positive results last week from ABSORB, the world’s first clinical trial evaluating the ...
May 27, 2007May 29, 2007 — Medtronic Inc. has enrolled the first patient in the landmark PROTECT clinical study, the largest ...
May 27, 2007May 29, 2007 — Boston Scientific Corp. has received CE Mark for its TAXUS Liberte Long paclitaxel-eluting coronary stent ...
May 27, 2007May 23, 2007 — XTENT Inc. announced positive six-month follow-up data from the CUSTOM II clinical trial, which assessed ...
May 21, 2007May 18, 2007 — According to a report published Thursday in the Wall Street Journal and posted on UPI, the number of ...
May 17, 2007May 16, 2007 — Stentys has announced that the results of preclinical testing of its bifurcated stent will be reported on ...
May 15, 2007May 16, 2007 — Boston Scientific Corp. has announced that it has completed enrollment in the European and ...
May 15, 2007© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now